35 results
8-K
EX-99.1
QLGN
Qualigen Therapeutics Inc
15 Aug 23
Results of Operations and Financial Condition
10:04am
expenses and other current liabilities
R&D grant liability
Deferred revenue, current portion
Operating lease liability, current portion
Short term debt
8-K
EX-99.2
QLGN
Qualigen Therapeutics Inc
26 Jul 23
Entry into a Material Definitive Agreement
5:25pm
:
Accounts payable
Accrued vacation
Accrued expenses and other current liabilities
R&D grant liability
Deferred revenue, current portion
Operating
8-K
EX-99.1
lf8pjsvc3dkahf372r
16 Aug 22
Qualigen Therapeutics, Inc. Reports Second Quarter 2022 Financial Results and Provides Corporate Update
6:20am
10-KT
k1e3t
31 Mar 21
Annual report (with FYE transition)
4:33pm
8-K/A
EX-99.1
bnkpkkya abshe
29 Jun 20
Index to Financial Statements
12:00am
8-K
EX-10.11
xf5e6vq
29 May 20
Qualigen Therapeutics Announces Merger Closing
5:03pm
CORRESP
oox sdv9ff
27 Mar 20
Correspondence with SEC
12:00am
S-4/A
EX-10.55
6sl8ds vhem975ad
13 Mar 20
Registration of securities issued in business combination transactions (amended)
5:28pm